EUVIMEDEUVIMED entdecken
Kohortenstudie

Real-World Evidence on the Use of Endocrine Therapy for Ductal Carcinoma In Situ in Patients Treated With Breast-Conserving Surgery Followed by Postoperative Radiation Therapy: A Brazilian Retrospective Cohort Study

Cecília Félix Penido Mendes de Sousa, Allan Andresson Lima Pereira, Gustavo Viani Arruda, Andre Guimaraes Gouveia, Samir Abdallah Hanna, Marcelo Rocha de Sousa Cruz, Carlos Henrique Dos Anjos, José Luis Barbosa Bevilacqua, Paulo Alcantara Filho, Fabio Ynoe de Moraes, Gustavo Nader Marta

Clinical Breast Cancer · 2023-12 · 23 (8) · e499-e506

DOI: 10.1016/j.clbc.2023.08.005 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Breast Cancer, 2023-12. Verfasst von Cecília Félix Penido Mendes de Sousa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Hospital Sírio Libanês, São Paulo, SP, Brazil. Electronic address: ceciliapenido.ro@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION/BACKGROUND: This study aims to evaluate the reproducibility of findings from randomized controlled trials regarding adjuvant hormone therapy (HT) for breast ductal carcinoma in situ (DCIS) in a real-life scenario. MATERIALS/METHODS: This retrospective cohort study used Fundação Oncocentro de São Paulo database. It included DCIS patients DCIS who received breast-conserving surgery and postoperative radiation therapy. The endpoints were local control (LC), breast cancer-specific survival (BCSS), and overall survival (OS). RESULTS: We analyzed 2192 patients treated between 2000 and 2020. The median FU was 48.99 months. Most patients (53.33%; n = 1169) received adjuvant HT. Patients not receiving adjuvant HT tend to be older (P = .021) and have a lower educational level (P < .001). At the end of FU, 1.5% of patients had local recurrence, and there was no significant difference between groups (P = .19). The 10-year OS and BCSS were 89.4% and 97.5% for adjuvant HT versus 91.5% and 98.5% for no adjuvant HT, respectively, and there were no significant differences between groups. The 10-year OS was 93.25% for medium/high education level versus 87.31% for low (HR for death 0.51; 95% CI, 0.32-0.83; P = .007). CONCLUSIONS: The benefits of adjuvant HT for DCIS were not reproduced in a Brazilian cohort. Education significantly impacted survival and HT usage, reflecting the influence of socioeconomic factors. These findings can allow for more precise interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingFemaleHumansAntineoplastic Agents, HormonalBrazilMastectomy, SegmentalNeoplasm Recurrence, LocalRadiotherapy, AdjuvantRandomized Controlled Trials as TopicReproducibility of ResultsRetrospective StudiesCohort Studies

Stichwörter der Autor:innen

AdjuvantAntineoplastic agents, HormonalBreast carcinoma in situRadiotherapyTamoxifen

Substanzen

Antineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Radiation Oncology, Hospital Sírio Libanês, São Paulo, SP, Brazil. Electronic address: ceciliapenido.ro@gmail.com.
  • Department of Medical Oncology, Hospital Sírio Libanês, Brasília, Brazil.
  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, SP, Brazil.
  • Department of Oncology, Division of Radiation Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada.
  • Department of Radiation Oncology, Hospital Sírio Libanês, São Paulo, SP, Brazil.
  • Department of Medical Oncology, Hospital Sírio Libanês, São Paulo, SP, Brazil.

Zitieren

APA

de Sousa, C. F. P. M., Pereira, A. A. L., Arruda, G. V., Gouveia, A. G., Hanna, S. A., Cruz, M. R. S., Dos Anjos, C. H., Bevilacqua, J. L. B., Alcantara Filho, P., de Moraes, F. Y., & Marta, G. N. (2023). Real-World Evidence on the Use of Endocrine Therapy for Ductal Carcinoma In Situ in Patients Treated With Breast-Conserving Surgery Followed by Postoperative Radiation Therapy: A Brazilian Retrospective Cohort Study. Clinical Breast Cancer, 23(8), e499-e506. https://doi.org/10.1016/j.clbc.2023.08.005

Vancouver

de Sousa CFPM, Pereira AAL, Arruda GV, Gouveia AG, Hanna SA, Cruz MRS, et al. Real-World Evidence on the Use of Endocrine Therapy for Ductal Carcinoma In Situ in Patients Treated With Breast-Conserving Surgery Followed by Postoperative Radiation Therapy: A Brazilian Retrospective Cohort Study. Clinical Breast Cancer. 2023;23(8):e499-e506. doi:10.1016/j.clbc.2023.08.005

BibTeX
@article{deSousa2023,
  author = {de Sousa, Cecília Félix Penido Mendes and Pereira, Allan Andresson Lima and Arruda, Gustavo Viani and Gouveia, Andre Guimaraes and Hanna, Samir Abdallah and Cruz, Marcelo Rocha de Sousa and Dos Anjos, Carlos Henrique and Bevilacqua, José Luis Barbosa and Alcantara Filho, Paulo and de Moraes, Fabio Ynoe and Marta, Gustavo Nader},
  title = {Real-World Evidence on the Use of Endocrine Therapy for Ductal Carcinoma In Situ in Patients Treated With Breast-Conserving Surgery Followed by Postoperative Radiation Therapy: A Brazilian Retrospective Cohort Study},
  journal = {Clinical Breast Cancer},
  year = {2023},
  volume = {23},
  number = {8},
  pages = {e499--e506},
  doi = {10.1016/j.clbc.2023.08.005}
}
Kostenlos starten →